# Procter & Gamble share price today (The Procter & Gamble Company, PG)

> The Procter & Gamble Company's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PG · Consumer Staples · Household & Personal Products · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/pg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: $162.06 (+7.8% in a year)
- P/E: 24.4× (lower than 63% of the last 4.6 years)
- Revenue (Sep 2026): $23.3 B (+4.0% on a year ago)
- Profit (Sep 2026): $4.8 B (−0.5% on a year ago)
- Operating margin: 27.1% (+0.3 points on a year ago)
- ROE: 30%, FY26
- ROIC: 21.9%, against a 5.9% cost of capital: +16.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Procter & Gamble share price today? The Procter & Gamble Company's share price was $162.06 at the close on 3 November 2026. It has been stalling near its high for 5 weeks. That is 8.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $142 and $167, and at that close it sat 80% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 10 years the share price moved +89% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Procter & Gamble pay? The Procter & Gamble Company paid $4.29 per share over the last four reported quarters. The most recent declaration was $1.09 for Sep 2026. At today's price of $162.06 that is a yield of 2.65%, based on dividends already paid, not a forecast. ## Which stock lists is Procter & Gamble on? Procter & Gamble is on 2 of our US lists: S&P 500 companies and Dow Jones 30 stocks. - [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)
- [Dow Jones 30 stocks](https://www.sectoralpha.in/dow-jones-stocks)

## Is Procter & Gamble profitable? The Procter & Gamble Company earned $4.8 B of net profit in the Sep 2026 quarter, −0.5% on the same quarter a year earlier. Full-year FY26 profit was $16.1 B. Over 5 years profit has grown 2.4% a year on average. That is 20.4% of the quarter's revenue. The same quarter a year earlier earned $4.8 B. Why profit moved: revenue changed +4.0% on a year earlier and the margin moved +0.3 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −4.6% and revenue +3.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Procter & Gamble make, and is it growing? The Procter & Gamble Company reported $23.3 B of revenue in the Sep 2026 quarter, +4.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 5 years it has grown 2.7% a year on average. The last full year, FY26, came in at $87.0 B. The last four reported quarters add to $87.9 B. FY26 revenue was $87.0 B, +3.3% on the year before. Recent pace: the last four quarters grew +3.6% on average, against 2.7% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.5%, against +2.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −4.4%, against +5.8% a year (rolling over). ## How much of every $100 of sales does Procter & Gamble keep? The Procter & Gamble Company's operating margin was 27.1% in the Sep 2026 quarter, 0.3 percentage points higher than the same quarter a year ago. Across 6 years it has been between 22.8% and 25.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +0.3 percentage points on the year while gross margin changed −1.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Procter & Gamble's profit turning into cash? Over the last 3 years, 121% of The Procter & Gamble Company's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $19.6 B of operating cash against $16.1 B of profit. After $4.4 B of spending on assets, $15.1 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Procter & Gamble's cash go? The Procter & Gamble Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $11.5 B on assets over the last 3 years. Averaged over those years that is 4.4% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $11.5 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Procter & Gamble's P/E ratio, and how does it compare with its own history? The Procter & Gamble Company's P/E is 24.4×, in the middle of its own history: higher than 37% of past readings. Its usual P/E (the middle reading) is 25.2×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +1.8% while the price moved +7.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +2.6% a year; about +2.5% a year came from earnings growth and about +0.1 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Procter & Gamble business getting better or worse? The Procter & Gamble Company's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +7.3% at its peak to −4.4% now), while ROCE is still 24.4%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Procter & Gamble earn on its capital? The Procter & Gamble Company earned a ROE of 30% in FY26. Its return on capital used (ROIC) is 16.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 18.5% net margin and 0.69× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 18.5% net margin × 0.69× asset turnover × 2.33× leverage (assets divided by equity) ≈ 29.7% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 21.9% − 5.9% = +16.0 percentage points. The 5.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Procter & Gamble have too much debt? The Procter & Gamble Company has total debt of $38.9 B against shareholder equity of $55.3 B as of Sep 2026, so its debt is 0.70× its equity. Year by year, that ratio went from 0.69 in FY21 to 0.64 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Procter & Gamble shareholding pattern? 0.9% of The Procter & Gamble Company's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 2.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Procter & Gamble from balance-sheet trouble? For The Procter & Gamble Company, the Z-score is 5.20. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.20 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Procter & Gamble rank in its industry? 58.1 out of 100, rank 4 of 20 in Household & Personal Products, with 85% of the evidence available. The Procter & Gamble Company scores 58.1 out of 100 against the 20 companies it is compared with in Household & Personal Products, ranking 4. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 19.7 + 21.2 + 6.7 + 10.5 = 58.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Procter & Gamble compared with? Procter & Gamble ranks 4 of 20 Household & Personal Products companies on the 4-Factor Sector Score, with 58.1 out of 100. 1. [Kenvue Inc.](https://www.sectoralpha.in/us/stocks/kvue) KVUE · Evidence leans up · 61% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.7/43.75 · Revenue 1.8% · Profit 16.9% · Operating margin change -0.4 points · 83% evidence Capital efficiency 21.1/31.25 · ROCE 14.4% · Operating margin 19.4% · 76% evidence Valuation 15.1/25 · P/E 22.2× · PEG 1.37 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 27.7 + 21.1 + 15.1 = 63.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 2. [Church & Dwight Co., Inc.](https://www.sectoralpha.in/us/stocks/chd) CHD · turning · Evidence leans up · 81% evidence 61.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.6/35 · Revenue 2.7% · Profit 41.9% · Operating margin change -2.7 points · 83% evidence Capital efficiency 15.8/25 · ROCE 14.6% · Operating margin 18.1% · 76% evidence Valuation 14.3/20 · P/E 30.8× · PEG 0.66 · 65% evidence Relative strength 13.1/20 · Lead over its industry 1.3% · Lead over S&P 500 8.7% · 1 year 25.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.6 + 15.8 + 14.3 + 13.1 = 61.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [The Estée Lauder Companies Inc.](https://www.sectoralpha.in/us/stocks/el) EL · leader · Evidence leans up · 64% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 5% · Profit n/a · Operating margin change 2.7 points · 62% evidence Capital efficiency 11.0/25 · ROCE 12.3% · Operating margin 7% · 76% evidence Valuation 11.5/20 · P/E -104.7× · PEG n/a · 15% evidence Relative strength 13.2/20 · Lead over its industry 0% · Lead over S&P 500 6.7% · 1 year 20.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.7 + 11 + 11.5 + 13.2 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. The Procter & Gamble Company this page PG · turning · Evidence leans up · 85% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 3.5% · Profit -4.4% · Operating margin change 0.3 points · 95% evidence Capital efficiency 21.2/25 · ROCE 24.6% · Operating margin 27.1% · 76% evidence Valuation 6.7/20 · P/E 21.4× · PEG 2.4 · 65% evidence Relative strength 10.5/20 · Lead over its industry -3.3% · Lead over S&P 500 3.7% · 1 year 10.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 21.2 + 6.7 + 10.5 = 58.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 5. [Colgate-Palmolive Company](https://www.sectoralpha.in/us/stocks/cl) CL · turning · Evidence leans up · 81% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 5.2% · Profit -29.2% · Operating margin change 0.1 points · 83% evidence Capital efficiency 21.1/25 · ROCE 40.8% · Operating margin 21% · 76% evidence Valuation 7.7/20 · P/E 36× · PEG 2.18 · 65% evidence Relative strength 8.1/20 · Lead over its industry -3.6% · Lead over S&P 500 3.4% · 1 year 21.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.2 + 21.1 + 7.7 + 8.1 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Acme United Corporation](https://www.sectoralpha.in/us/stocks/acu) ACU · leader · Evidence leans up · 81% evidence 53.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.8/35 · Revenue 9.3% · Profit -9.1% · Operating margin change -0.9 points · 83% evidence Capital efficiency 10.9/25 · ROCE 8.7% · Operating margin 10.9% · 76% evidence Valuation 6.7/20 · P/E 18.5× · PEG 2.5 · 65% evidence Relative strength 19.1/20 · Lead over its industry 28% · Lead over S&P 500 36.8% · 1 year 88.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 16.8 + 10.9 + 6.7 + 19.1 = 53.5 · What this means: Relative strength against the index is 36.8%, and revenue and profit growth are weak. 7. [Interparfums, Inc.](https://www.sectoralpha.in/us/stocks/ipar) IPAR · quiet · Evidence leans up · 81% evidence 52.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 2.9% · Profit 4.4% · Operating margin change -5.4 points · 83% evidence Capital efficiency 17.9/25 · ROCE 21% · Operating margin 12.3% · 76% evidence Valuation 9.7/20 · P/E 21.4× · PEG 1.99 · 65% evidence Relative strength 10.9/20 · Lead over its industry 3% · Lead over S&P 500 10.3% · 1 year 34% · 100% evidence · 5 of 12 weeks ahead Exact sum: 13.9 + 17.9 + 9.7 + 10.9 = 52.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kimberly-Clark Corporation](https://www.sectoralpha.in/us/stocks/kmb) KMB · basing · Evidence leans up · 81% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.1/35 · Revenue 0.7% · Profit -18.9% · Operating margin change 2.8 points · 83% evidence Capital efficiency 20.6/25 · ROCE 24.6% · Operating margin 19% · 76% evidence Valuation 7.6/20 · P/E 18.6× · PEG 2.38 · 65% evidence Relative strength 5.2/20 · Lead over its industry -10% · Lead over S&P 500 -3.6% · 1 year 0.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 17.1 + 20.6 + 7.6 + 5.2 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Newell Brands Inc.](https://www.sectoralpha.in/us/stocks/nwl) NWL · losing its lead · Evidence leans up · 64% evidence 50.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue -2% · Profit n/a · Operating margin change 5.2 points · 62% evidence Capital efficiency 8.6/25 · ROCE 7.3% · Operating margin 14.7% · 76% evidence Valuation 11.0/20 · P/E -11.8× · PEG n/a · 15% evidence Relative strength 11.4/20 · Lead over its industry 8.6% · Lead over S&P 500 16% · 1 year 77.6% · 100% evidence · 7 of 12 weeks ahead Exact sum: 19.3 + 8.6 + 11 + 11.4 = 50.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Helen of Troy Limited](https://www.sectoralpha.in/us/stocks/hele) HELE · turning · Evidence leans down · 67% evidence 49.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.8/35 · Revenue 0.3% · Profit n/a · Operating margin change -2.6 points · 71% evidence Capital efficiency 9.4/25 · ROCE 9.8% · Operating margin 0.5% · 76% evidence Valuation 10.7/20 · P/E -7.1× · PEG n/a · 15% evidence Relative strength 14.3/20 · Lead over its industry 13.8% · Lead over S&P 500 22.2% · 1 year 52.3% · 100% evidence · 2 of 12 weeks ahead Exact sum: 14.8 + 9.4 + 10.7 + 14.3 = 49.2 · What this means: Relative strength against the index is 22.2%, and revenue and profit growth are weak. 11. [e.l.f. Beauty, Inc.](https://www.sectoralpha.in/us/stocks/elf) ELF · leader · Evidence leans down · 81% evidence 48.7 out of 100 Growth Capital Valuation Relative
12. [Spectrum Brands Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spb) SPB · quiet · Evidence leans down · 81% evidence 45.1 out of 100 Growth Capital Valuation Relative
13. [Coty Inc.](https://www.sectoralpha.in/us/stocks/coty) COTY · breaking out · Evidence leans down · 64% evidence 44.3 out of 100 Growth Capital Valuation Relative
14. [Edgewell Personal Care Company](https://www.sectoralpha.in/us/stocks/epc) EPC · turning · Evidence leans down · 71% evidence 41.6 out of 100 Growth Capital Valuation Relative
15. [Magnera Corporation](https://www.sectoralpha.in/us/stocks/magn) MAGN · quiet · Evidence leans down · 64% evidence 39.4 out of 100 Growth Capital Valuation Relative
16. [The Clorox Company](https://www.sectoralpha.in/us/stocks/clx) CLX · basing · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative
17. [The Honest Company, Inc.](https://www.sectoralpha.in/us/stocks/hnst) HNST · losing its lead · Evidence leans down · 71% evidence 35.0 out of 100 Growth Capital Valuation Relative
18. [Nu Skin Enterprises, Inc.](https://www.sectoralpha.in/us/stocks/nus) NUS · basing · Most evidence points down · 71% evidence 30.6 out of 100 Growth Capital Valuation Relative
19. [Oddity Tech Ltd.](https://www.sectoralpha.in/us/stocks/odd) ODD · breaking out · Most evidence points down · 81% evidence 24.7 out of 100 Growth Capital Valuation Relative
20. [Unilever PLC](https://www.sectoralpha.in/us/stocks/ul) UL · turning · Too little evidence to rank firmly · 47% evidence 50.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Household & Personal Products](https://www.sectoralpha.in/us/sectors/household-personal-products), all 20 compared on one page. ## Which companies are close to Procter & Gamble in size? Procter & Gamble is the largest of 22 Household & Personal Products companies on Sector Alpha by market value (scores of 3 November 2026). It is the largest. Just below it: Unilever PLC, Colgate-Palmolive Company, The Estée Lauder Companies Inc., Kenvue Inc., Kimberly-Clark Corporation and Church & Dwight Co., Inc. ### Household & Personal Products companies close in size

1. The Procter & Gamble Company $375.6 billion
2. [Unilever PLC](https://www.sectoralpha.in/us/stocks/ul) $140.3 billion
3. [Colgate-Palmolive Company](https://www.sectoralpha.in/us/stocks/cl) $76 billion
4. [The Estée Lauder Companies Inc.](https://www.sectoralpha.in/us/stocks/el) $38.1 billion
5. [Kenvue Inc.](https://www.sectoralpha.in/us/stocks/kvue) $37.1 billion
6. [Kimberly-Clark Corporation](https://www.sectoralpha.in/us/stocks/kmb) $34.7 billion
7. [Church & Dwight Co., Inc.](https://www.sectoralpha.in/us/stocks/chd) $25.8 billion

[All 22 Household & Personal Products companies, largest first](https://www.sectoralpha.in/us/sectors/household-personal-products#all-companies)

### Companies close in size in other industries

1. [The Coca-Cola Company](https://www.sectoralpha.in/us/stocks/ko) $412.3 billion · Beverages - Non-Alcoholic
2. [Cisco Systems, Inc.](https://www.sectoralpha.in/us/stocks/csco) $400 billion · Communication Equipment
3. The Procter & Gamble Company $379.1 billion
4. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) $366 billion · Drug Manufacturers - General
5. [Oracle Corporation](https://www.sectoralpha.in/us/stocks/orcl) $361.4 billion · Software - Infrastructure

## What else do people ask about Procter & Gamble? ### What is Procter & Gamble's stock price today? The Procter & Gamble Company's stock price is $162.06, +7.8% over the past year. The whole company is worth $376 B on the market. In the last 52 weeks it traded between $142 to $167; today it is 80% of the way up from the low, 8.7% above its 200-day average (as of 3 November 2026). ### What were Procter & Gamble's latest quarterly results? The Procter & Gamble Company reported revenue of $23.3 B and net profit of $4.8 B for the Sep 2026 quarter. Revenue rose 4.0% and profit fell 0.5% compared with a year earlier. Earnings per share were $1.97 (as of 3 November 2026). ### What is Procter & Gamble's market cap? The Procter & Gamble Company's market capitalisation is $376 B at a stock price of $162.06. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Procter & Gamble performing? The Procter & Gamble Company's share price has been stalling near its high for 5 weeks. In its latest quarter, revenue rose 4.0% and profit fell 0.5% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running (as of 3 November 2026). ### Will Procter & Gamble's stock price go up? This page does not forecast The Procter & Gamble Company's stock price. What it shows instead: the stock price is $162.06, and it has been stalling near its high for 5 weeks. Its P/E of 24.4× is higher than 37% of its own last 5 years (as of 3 November 2026). ### Where is Procter & Gamble in its business cycle? The Procter & Gamble Company's FY26 operating margin was 24.8%, against a 6-year range of 22.8% to 25.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 27.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Procter & Gamble story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Procter & Gamble a stock worth studying right now? What the numbers show: The Procter & Gamble Company's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks
- Dow Jones 30 stocks: https://www.sectoralpha.in/dow-jones-stocks

This is research, not advice. We’re not SEBI-registered.